Apixaban

Drug Profile

Apixaban

Alternative Names: BMS-562247; BMS-562247-01; Eliquis

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Bristol-Myers Squibb; Pfizer
  • Class 2 ring heterocyclic compounds; Amides; Anticoagulants; Antithrombotics; Lactams; Phenyl ethers; Pyrazoles; Pyridones; Small molecules
  • Mechanism of Action Factor Xa inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Deep vein thrombosis; Pulmonary embolism; Stroke; Thromboembolism; Venous thromboembolism
  • Phase III Acute coronary syndromes

Most Recent Events

  • 13 Apr 2017 Pfizer and Bristol-Myers Squibb completes the phase III AVERROES trial in Stroke (Prevention) in USA, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Finland, France, Germany, Greece, Hong Kong, India, Indonesia, Israel, Italy, South Korea, Malaysia, Mexico, Norway, Philippines, Poland, Russia, Singapore, South Africa, Spain, Sweden, Taiwan, Turkey, Ukraine and United Kingdom (PO) (NCT00496769) (EudraCT2007-001557-26)
  • 23 Feb 2017 Bristol-Myers Squibb has patent protection for apixaban in Japan (Pfizer Form 10-K, February 2017)
  • 01 Jan 2017 Phase-II clinical trials in Thromboembolism (In adolescents, In children, In infants, Prevention) in USA (PO, Tablet) (NCT02981472)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top